Table 2 IC50 concentrations expressed in μM for the in vitro cell growth inhibition induced by exposure to fascaplysin (1), CA198 (3), CA199 (4), CA211 (5) and BPT (6) for 48 h and measured by MTT assay
From: Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization
Cell lines | Fascaplysin (1) | CA198 (3) | CA199 (4) | CA211 (5) | BPT (6) |
|---|---|---|---|---|---|
LS174T (colorectal carcinoma; p53+, pRb+) | 0.88+0.04 | 33+2.5 | 7.1+1.3 | 29+2 | 0.85+0.07 |
PC-3 (prostate; p53 null, pRb+) | 0.92+0.06 | 42+3 | 13.1+1.8 | 32+1.5 | 0.74+0.09 |
MiaPaCa (pancreatic; p53His273mut, pRb+) | 0.88+0.2 | 43+5 | 8.5+ 1.3 | 29+4.5 | 0.8+0.1 |
A549 (NSCLC; p53+, pRb+) | 0.69+0.03 | 46+4 | 8.0+2 | 31+3.5 | 0.92+0.08 |
Calu-1 (NSCLC; p53 null, pRb+) | 1.3+0.1 | 92+4.5 | 47+3.5 | 54+4 | 2.8+0.4 |
NCI-H460 (NSCLC; p53+, pRb+) | ND | 29+3.5 | 6.2+0.7 | 22+2 | 0.6+0.06 |
NCI-H1299 (NSCLC; p53 null, pRb+) | ND | 35+2 | 4.5+0.5 | 30+1 | 0.9+0.045 |
NCI-H358 (NSCLC; p53 null, pRb null) | ND | 28+4 | 3.5+0.8 | 25+1.5 | 0.68+0.07 |
BNL CL2 (mouse normal hepatic cells) | ND | 37+1.5 | 6.5+0.7 | 27+2.5 | 0.72+0.1 |
BNL SV A.8 (mouse hepatic; SV40-mediated transformed cells) | ND | 40+3.5 | 8.2+1 | 35+3 | 0.75+0.08 |
